Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD Study of Tinlarebant (LBS-008) in Healthy Adults
NCT03735810Phase 1Completed
- Sponsor
- RBP4
- Start
- Nov 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tinlarebant in Stargardt disease (STGD) and age-related macular degeneration (AMD) (9 arms), sponsored by RBP4. Primary endpoints: Area under the plasma concentration versus time curve from time 0 to the last timepoint with quantifiable concentration, Area under the plasma concentration versus time curve from time 0 extrapolated to infinity and 7 more. Started Nov 2018; status: completed.
02
Drugs
tinlarebant
03
Conditions
Stargardt disease (STGD)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT03735810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03735810.